HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amazon Response About Drug-Spiked Supplements ‘Not Sufficient To Protect Public’ – FDA

Executive Summary

“Amazon has taken some action when alerted by the FDA about sales” of violative supplements, but FDA "found that other such products continue to be offered for sale” by the firm through its Fulfillment by Amazon service, according to untitled letter.

You may also be interested in...



Amazon Testing Update Could, As FDA And Industry Want, Purge Bad Actors From Supplement Market

Latest update to Amazon’s screening policy for supplements requires showing sexual enhancement and weight loss products have been tested by third-party labs and lays out additional requirements for all supplement products.

US FDA Testing Finds Consumer Health Market Problems, But It Can’t Test Entire Marketplace

CDER compliance office director Donald Ashley offers a cautionary note to temper expectations for the FDA’s enforcement in the supplement sector. “We continue to warn the public about products very often sold as dietary supplements that contain hidden drugs,” he says.

US FDA Put On The Clock About NAC's Use As Dietary Ingredient After Amazon Ends Sales

Trade group asked FDA six months ago to reverse position it revealed in July 2020 that products containing NAC cannot be marketed as dietary supplements. After Amazon in May reported pulling NAC supplements from its site, CRN decided to ask again.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS151603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel